Author: Meuleman E.J.

Source: Expert Opinion on Pharmacotherapy, Volume 4, Number 11, 1 November 2003 , pp. 2049-2056(8)

Publisher: Informa Healthcare

Abstract:

Approximately 150 million men worldwide experience erectile dysfunction (ED) whereby they are unable to achieve and maintain an erection adequate for satisfactory sexual performance. ED has a considerable impact on quality of life. Tadalafil (Cialis™, Eli Lilly & Co./ICOS) is a novel effective and safe phosphodiesterase type 5 inhibitor, a secondary messenger for the smooth muscle relaxing effects of nitric oxide, which plays a central role in the vasodilation of erectile tissues. It has a longer half-life than sildenafil. As head-to-head comparative trials are lacking, it is not clear what tadalafil offers over sildenafil. In terms of marketing, much is made of the ‘spontaneity’ achievable because of the (relatively) longer half-life of tadalafil.

Keywords: erectile dysfunction; phosphodiesterase type 5 inhibition; tadalafil; treatment

Document Type: Drug Evaluation

Publication date: 2003-11-01

More about this publication?

• Editorial Board
• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Meuleman E.J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers